

Pictet - Health - I dy USD

Risk and reward profile

Don't take unnecessary risks.
Read the Key Investor
Information Document.



Market review

Russia's invasion of Ukraine has roiled financial markets, causing a steep sell-off in equities and a rally in gold and oil. The military assault could have serious consequences for the global economy, but the range of possible outcomes is wide. Faced with a number of unpalatable scenarios, investors could be forgiven for wanting to shore up their defenses. Yet we would caution against taking drastic measures. If a protracted conflict can be avoided, the economic fallout should remain manageable, allowing the world to build on its recovery from the pandemic.

Performance analysis

The Health strategy outperformed the MSCI ACWI for the month. Humana, Steris and Boston Scientific were among the best contributors. Humana had a rough January when management published the full-year guidance. However, the Medicare Advantage rates proposal was better than expected and managed care stocks moved higher in February. Steris delivered solid quarterly numbers and raised the guidance for the full year thanks to solid growth across the business and higher cost synergies from a recent acquisition. Boston Scientific's share price was rather stable and held up well in a market that was under pressure. Clorox, Garmin and Thermo Fisher were among the bottom contributors. Clorox clearly struggled with cost inflation and the supply chain, which sent the shares lower. Garmin delivered good full-year numbers, but the market was expecting a better margin guidance for the new year. Thermo Fisher's share price declined without major news.

Portfolio activity - overweightings & underweightings

We built a position in Colgate as we see the company is well positioned in the oral care company. Colgate is also active in the personal and home care spaces and owns an attractive pet nutrition business. Its strong brands should allow the company to better cope with inflationary pressures than many peers. We financed the position with Clorox shares. We discussed this in the section above. We believe the company has to face a bigger and longer than expected impact from inflation on its margins. We sold Seagen as the company's revenue guidance for 2022 came in as much weaker than anticipated, and with consensus expectations still high, we see risk to further disappointments over the year while valuation support has disappeared.

Market outlook

With a medium- to long-term view, there are several fundamental reasons why we think the health theme is set to perform. Above all, the demographic shift as the world grows older creates the challenge of more age-related disease. Therefore, in an ageing society, keeping people healthy for longer is the key to curb healthcare spending growth. Scientific innovation and progress in medical research are leading to better, more efficient standards of care. Despite all the progress on the scientific front, healthcare costs are also rising rapidly due to inefficiencies and wasted resources in the system. Technology has disruptive potential in this area and companies that are able to enable both better care and better efficiency are poised to capture attractive markets for themselves. Further, as wealth increases, so do people's focus on health. From investing in personal care and home care to staying healthy through lifestyle changes, consumers are taking their health into their own hands. In fact, preventing health issues is an extremely cost-effective strategy and governments are eager to incentivize such behaviours, as can be seen with guidelines or even financial disincentives on certain unhealthy products. In fact, preventing health issues is an extremely cost-effective strategy and governments are eager to incentivize such behaviours, as can be seen with guidelines or even financial disincentives on certain unhealthy products.

Portfolio strategy

We want to gain exposure to players that are finding new ways to increase the health of the population across the globe. We look for innovators in healthcare that significantly improve the standard of care as well as the outcome for patients, restoring their health as much as possible. We look for innovators in healthcare that significantly improve the standard of care as well as the outcome for patients, restoring their health as much as possible. Finally, firms that can make healthcare more efficient and ensure that patients have proper access to care are essential to free up resources while optimizing patient outcomes, thereby helping to finance health.

General information

Legal form	Sub-fund of a SICAV
Regulatory status	UCITS
Domicile	Luxembourg
Inception date	03.09.2013
Launch date	03.09.2013
Share class currency	USD
Compartment currency	USD
ISIN	LU0953041927
Reference index	MSCI AC World (USD)
Min. investment horizon (year(s))	5

Fees

Ongoing charges (OCR)	1.12%
Performance fee (excluded from OCR)	-
Management fee (included in OCR)	0.80%
Max. conversion fee	2.00%
Max. subscription fee	5.00%
Max. redemption fee	1.00%

Management team

Moritz Dullinger
Grégoire Biollaz
Tazio Storni
Lydia Haueter

Source: Pictet Asset Management

Further information can be found in the prospectus.

Pictet Asset Management

For further information,
please visit our website
assetmanagement.pictet

Important Information

This marketing material is issued by the Fund Management Company, Pictet Asset Management (Europe) S.A., a company authorized and regulated by the Luxembourg regulator "Commission de Surveillance du Secteur Financier". It is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The information contained in this document is for information purposes only. It cannot be used as a basis for subscription and does not form part of a contract. The latest version of the fund's prospectus, Key Investor Information Document, annual and semi-annual reports must be read before investing. They are available in English and in the local language of each country where the compartment is registered, free of charge on www.assetmanagement.pictet or at Pictet Asset Management (Europe) S.A., 15 avenue J.F. Kennedy, L-1855 Luxembourg, or at the office of the Fund local agent, distributor or centralizing agent if any. In Switzerland, the representative agent is Pictet Asset Management S.A. and the paying agent is Banque Pictet & Cie S.A. Pictet Asset Management (Europe) S.A. has not taken any steps to ensure that the securities referred to in this document are suitable for any particular investor and this document is not to be relied upon in substitution for the exercise of independent judgment. Tax treatment depends on the individual circumstances of each investor and may be subject to change in the future. Before making any investment decision, investors are recommended to ascertain if this investment is suitable for them in light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional. Holdings do not represent the full portfolio. There is no guarantee that these securities will be held in the future and you should not assume that investment in the securities listed was, or will be profitable. Any reference to a ranking, a rating or an award provides no guarantee for future performance results and is not constant over time. For hedged share classes, only the compartment's consolidation currency is hedged into the share class currency. Foreign exchange exposure, resulting from assets in the portfolio which are not denominated in the consolidation currency, can remain. NAVs relating to dates on which shares are not issued or redeemed ("non-trading NAVs") in your country may be published here. They can only be used for statistical performance measurements and calculations or commission calculations and cannot under any circumstances be used as a basis for subscription or redemption orders. The published performance represents past data. Past performance may not be a reliable guide to future performance. There is no guarantee that the same yields will be obtained in the future. The value and income of any of your investments may fluctuate with market conditions and may lose some or all its value. The fund may be affected by changes in currency exchange rates, which can have an adverse effect on the value or income of the fund. Performance is shown based on the share class NAV per share (in the share class currency) with dividends reinvested (for distributing share classes), including actual ongoing charges, and excluding subscription/redemption fees and taxes borne by the investor. Inflation was not taken into account. As a subscription fee calculation example, if an investor invests EUR 1000 in a fund with a subscription fee of 5%, he will pay to his financial intermediary EUR 47.62 on his investment amount, resulting with a subscribed amount of EUR 952.38 in fund shares. In addition, potential account keeping costs (by your custodian) may reduce the performance. Indices do not include fees or operating expenses and you cannot invest in them.

Any index data referenced herein remains the property of the Data Vendor. Data Vendor Disclaimers are available on assetmanagement.pictet under "Resources" section.

No part of this material may be copied or redistributed without Pictet Asset Management prior written consent. ©2019 Pictet